Replies to post #23146 on Regen BioPharma Inc (RGBP)

[Shotime66]

Doesn't look like a bad thing at all. Keep watching.

$$$$$$$$$$$$$$$$$$ RGBP $$$$$$$$$$$$$$$$$$$$

[fuzzyforeigner]

bad PR? nobody even notices this stuff. it requires digging, which 99% of traders and likely 90% of investors won't do.

[cvinvestor]

The PR that T. Ichim left RGBP because of health reasons is indeed very questionable. That said, let us remember that T. Ichim helped to cofound Batu before he was hired by RGBP. Why he left Batu for RGBP and then why he left RGBP to return to Batu is problematic, but it may come down to personalities and it may be that Batu's ValloVax is further along than RGBP's dCellVax and T. Ichim was offered a sweeter deal at Batu or a better working relationship.

Also interesting that the Batu PR doesn't even mentioned T. Ichim having been the Chief Scientific Officer at RGBP and the PR contact has the same woman "Dorsee" that RGBP recently hired for it's PRs.

There's definitely a lot of crossover and questions about the relationships these scientists have between the many companies that vie for their names and research. What doesn't change is that yes, T. Ichim did sign over and sell some of his patents and research to RGBP, (it wasn't everything he's ever been involved with, but specific things to RGBP's pipeline). But what RGBP acquired stays with RGBP.

While T. Ichim was Chief Scientific Officer, let's not forget that it has been C. Ichim who has headed up the research and presentations regarding NR2F6 which may be the current focus of the RGBP pipeline development outside of HemaX. And RGBP has contract with Dr. Kesari regarding dCellVax IND research. Now that RGBP has contracted with NIH/NCATS for the compound hits development and fine tuning for NR2F6 and owns a proprietary compound hit process internally, its pipeline development is clearly not dependent on T. Ichim. If we hear news of C. Ichim leaving, then serious red flags arise as from my recollection, she pretty much is all in with RGBP for her research and loses IP if she leaves. T. Ichim loses the IP property that RGBP bought that as I recall was related to dCellVax or DiffronC research.

While his leaving under a questionable PR reason is cause for concern, it is not a death toll. As I stated, Batu, which he helped to found is near clinical trials for ValloVax, T. Ichim may have personally decided that was what he wanted to pursue whole heartedly at this time.